TOXICAN: a Guide for Grading Dermatological Adverse Events of Cancer Treatments

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2018 Mar 14

PMID 29532244

Citations 1

Authors

L Peuvrel

J Cassecuel

C Bernier

G Quereux

M Saint-Jean

M Le Moigne

C Frenard

A Khammari

B Dreno

Affiliations

Soon will be listed here.

Abstract

Purpose: The dermatological toxicity of cancer treatments is frequent and sometimes debilitating. Its reference classification, the NCI-CTCAE (National Cancer Institute-Common Terminology Criteria for Adverse Events), is sometimes difficult to use and does not include yet the newest toxicities. Our objective was to create a guide, TOXICAN, based on the CTCAE, which is easy to use in everyday practice and which facilitates the recognition and grading of these dermatological toxicities.

Methods: This guide was developed by a working group ("GESTIM") comprising oncodermatologists, allergists, pathologists, and researchers from Nantes University Hospital. It was based on the dermatological toxicities found in the CTCAE and adapted to daily practice. These toxicities were grouped into categories and associated with photographs of typical cases to aid recognition. A simplified grading scale derived from the CTCAE was also created. This booklet was validated by means of user evaluation, and then the Delphi consensus method.

Results: We selected 32 dermatological toxicities, including 12 created by our group, sorted into 7 categories: skin rash, dry skin/pruritus, hyperkeratotic papules, palmoplantar changes, hair and nail changes, mucosal changes, and others. Our simplified grading scale only differed from the CTCAE for one item, urticaria. Three items were modified after evaluation by the user group and 11 after application of the Delphi method.

Conclusion: The objective of our practical guide is to facilitate the use of the CTCAE for recognizing and grading dermatological toxicity of cancer treatments in order to provide optimal guidance for therapeutic adaptations. Its impact on clinical practice remains to be evaluated.

Citing Articles

A survey of accuracy of nurses' clinical judgement of cutaneous graft-versus-host disease in Japan.

Maeda R, Obama K, Tomioka A, Akagawa J, Maru M Nurs Open. 2021; 8(2):646-655.

PMID: 33570303 PMC: 7877142. DOI: 10.1002/nop2.669.

References

Jiang G, Wang L, Liu H, Solbrig H, Chute C . Building a knowledge base of severe adverse drug events based on AERS reporting data using semantic web technologies. Stud Health Technol Inform. 2013; 192:496-500. View

Hay J, Atkinson T, Reeve B, Mitchell S, Mendoza T, Willis G . Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Qual Life Res. 2013; 23(1):257-69. PMC: 3896507. DOI: 10.1007/s11136-013-0470-1. View

Deng J, Ridner S, Dietrich M, Wells N, Murphy B . Assessment of external lymphedema in patients with head and neck cancer: a comparison of four scales. Oncol Nurs Forum. 2013; 40(5):501-6. DOI: 10.1188/13.ONF.501-506. View

Liu Y, Zhu G, Guan X . Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma. Oral Oncol. 2012; 48(6):554-9. DOI: 10.1016/j.oraloncology.2012.01.004. View

Lacouture M, Anadkat M, Bensadoun R, Bryce J, Chan A, Epstein J . Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011; 19(8):1079-95. PMC: 3128700. DOI: 10.1007/s00520-011-1197-6. View

Kluetz P, Chingos D, Basch E, Mitchell S . Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book. 2016; 35:67-73. DOI: 10.1200/EDBK_159514. View

Bergman H, Walton T, Del Bel R, Seki J, Rafii A, Xu W . Managing skin toxicities related to panitumumab. J Am Acad Dermatol. 2014; 71(4):754-9. DOI: 10.1016/j.jaad.2014.06.011. View

Peuvrel L, Dreno B . Dermatological toxicity associated with targeted therapies in cancer: optimal management. Am J Clin Dermatol. 2014; 15(5):425-44. DOI: 10.1007/s40257-014-0088-2. View

Palazzi M, Tomatis S, Orlandi E, Guzzo M, Sangalli C, Potepan P . Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system. Int J Radiat Oncol Biol Phys. 2007; 70(2):330-7. DOI: 10.1016/j.ijrobp.2007.06.022. View

10.

Chan A, Tan E . How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?. Support Care Cancer. 2010; 19(10):1667-74. DOI: 10.1007/s00520-010-0999-2. View

11.

Gonzalez-Sanchis A, Vicedo-Gonzalez A, Brualla-Gonzalez L, Gordo-Partearroyo J, Inigo-Valdenebro R, Sanchez-Carazo J . Looking for complementary alternatives to CTCAE for skin toxicity in radiotherapy: quantitative determinations. Clin Transl Oncol. 2014; 16(10):892-7. DOI: 10.1007/s12094-014-1163-0. View

12.

Fine L, Bernstein J . Urticaria Guidelines: Consensus and Controversies in the European and American Guidelines. Curr Allergy Asthma Rep. 2015; 15(6):30. DOI: 10.1007/s11882-015-0535-z. View

13.

Russo A, Taghian A . Fat necrosis of the breast in the accelerated partial breast irradiation era: the need for a universal grading system. Breast Cancer Res Treat. 2013; 140(1):1-11. DOI: 10.1007/s10549-013-2611-1. View

14.

Williams K, Sharma H . Anaphylaxis and urticaria. Immunol Allergy Clin North Am. 2014; 35(1):199-219. DOI: 10.1016/j.iac.2014.09.010. View

15.

Lencioni A, Hutchins L, Annis S, Chen W, Ermisoglu E, Feng Z . An adverse event capture and management system for cancer studies. BMC Bioinformatics. 2015; 16 Suppl 13:S6. PMC: 4597098. DOI: 10.1186/1471-2105-16-S13-S6. View

16.

Atkinson T, Li Y, Coffey C, Sit L, Shaw M, Lavene D . Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2011; 21(7):1159-64. PMC: 3633532. DOI: 10.1007/s11136-011-0031-4. View

17.

Zenda S, Ota Y, Tachibana H, Ogawa H, Ishii S, Hashiguchi C . A prospective picture collection study for a grading atlas of radiation dermatitis for clinical trials in head-and-neck cancer patients. J Radiat Res. 2016; 57(3):301-6. PMC: 4915537. DOI: 10.1093/jrr/rrv092. View

18.

Lynch Jr T, Kim E, Eaby B, Garey J, West D, Lacouture M . Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007; 12(5):610-21. DOI: 10.1634/theoncologist.12-5-610. View

19.

Trotti A, Colevas A, Setser A, Rusch V, Jaques D, Budach V . CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13(3):176-81. DOI: 10.1016/S1053-4296(03)00031-6. View

20.

Lacouture M, Maitland M, Segaert S, Setser A, Baran R, Fox L . A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010; 18(4):509-22. DOI: 10.1007/s00520-009-0744-x. View